For more information, please contact Brooke Powell at firstname.lastname@example.org or 614-846-6258.
Staff & Leadership
- Esteban Fernandez Faith, MD, FAAD – Medical Director
- Chris Peltier, MD, FAAP – Primary Care Expert
- Patricia Treadwell, MD, FAAD, FAAP – Content Expert
- Brooke Powell, CPhT – Program Manager
- The pilot QI project had 11 participating practices that aimed to improve screening, referral and management of AD.
- At baseline, 10% of providers were using resources with families they had prior to the project. In January 2021, providers using resources in the collaborative reached 71%, which was the highest during the project. The collaborative ended at 63% in June 2021.
- At baseline, the providers were using their own action plans for medication and treatment management. An eczema action plan was created and distributed to the providers in the collaborative. In January 2021, 72% of providers provided an action plan. The collaborative ended with 62% in June 2021.
- All project leaders reported they were “very confident” discussing AD and resources with families. This is an over 85% increase among those who participated.
- The AD pilot program created a diagnosis and management tool to measure and document AD with families. Providers who participated in the QI project helped create the tool and it was used by up to 70% of providers.
- Family rack cards were created for providers to educate families on AD. As a collaborative, these were also used up to 70%.
Literature and Resources
Atopic Dermatitis: Improving Care in Diverse Populations. This series as an educational supplement to the American Academy of Pediatrics, Ohio Chapter’s Atopic Dermatitis Quality Improvement Program.
Chris Peltier, MD, FAAP – Ohio AAP President, Pediatric Associates of Mount Carmel
Patricia A. Treadwell, MD, FAAD, FAAP – Indiana University School of Medicine
Esteban Fernandez Faith, MD – Nationwide Children’s Hospital
Topics: Background & Epidemiology; Clinical Presentation in AD in Skin of Color; Cultural Preference & Practices; AD Comorbidities & Psycho-social Impact; Treatment & Health Disparities; Hot Topics; and New Medications